Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report details a specific share repurchase transaction executed on March 21, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 200,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,523.5 pence per share; lowest price paid was 1,504 pence per share.
- Treasury Holdings (Settled): 497,621,327 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 497,821,327 shares (10.14% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,908,109,947 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 200,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.14% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure regarding share repurchase activity and voting rights calculations under the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (497,621,327 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,908,109,947 shares in issue) for disclosure threshold assessments.
- Review the price paid per share (1,504 to 1,523.5 pence) against the market price on March 21, 2013.
- Note that this filing does not contain operational or financial performance data for the period.